MINNEAPOLIS , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the three and nine months ended
MINNEAPOLIS , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the
MINNEAPOLIS , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has acquired rights to technology for the proprietary
Precision Therapeutics Files Form S-4 Regarding Proposed Merger with Helomics Holding Corporation MINNEAPOLIS , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine
MINNEAPOLIS , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Hector J. Gomez , President & CEO, Co-Founder of GLG
MINNEAPOLIS , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) is pleased to announce that its Skyline Medical division, producer of the FDA -approved and CE-marked STREAMWAY® System for automated, direct-to-drain medical fluid
MINNEAPOLIS , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”) is pleased to announce it has secured its first European sale of the STREAMWAY System® , an automated, direct-to-drain medical fluid disposal system sold by the Company’s
MINNEAPOLIS , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Robert Murphy to its Scientific Advisory Board . Dr.
MINNEAPOLIS , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has bolstered its Scientific Advisory Board with the appointment of Dr.
MINNEAPOLIS , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Dr.